French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Investigators at Dana-Farber Cancer Institute are opening a new clinical trial to evaluate a novel type of immune cellular ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

The hair follicle is a dynamic miniature organ. Its permanent portion opens to the skin surface, communicates with sebaceous ...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

They found that natural killer (NK) cells, a type of immune cell in our bodies that fights disease, become stronger and more ...